AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AgomAb Therapeutics NV

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026

$8.23−0.05 (-0.60%)

Close on Oct 19, 2026

AgomAb Therapeutics NV income statement

AnnualQuarterlyTTM

EUR USD

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research & Development	55	43	28
Operating Expenses	70	53	35
Operating Income	-67	-52	-34
Interest Expense	0.15	0.39	0.09
Interest & Investment Income	1.94	1.37	0.33
Pretax Income	-71	-50	-13
Income Tax Expense	–	0.00	-0.67
Net Income incl. Noncontrolling Interests	-71	-50	-12
Net Income	-71	-50	-12
Net Income to Common	-87	-63	-21
EPS (Basic)(per share)	-161.61	-115.84	-38.53
EPS (Diluted)(per share)	-161.61	-115.84	-38.53
Shares Outstanding (Basic, Weighted)(shares)	0.54	0.54	0.54
Shares Outstanding (Diluted, Weighted)(shares)	0.54	0.54	0.54
EBITDA	-67	-52	-34

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -39.2%

Financial strength

Current ratio: 6.52
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 464.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.